NADAC acquisition cost data for DUTASTERIDE-TAMSULOSIN 0.5-0.4. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 10370028009 | $2.02 | 2022-12-21 | Rx |
| 10370028011 | $2.02 | 2022-12-21 | Rx |
| 68382064006 | $2.02 | 2022-12-21 | Rx |
| 68382064016 | $2.02 | 2022-12-21 | Rx |
| 10370028009 | $2.02 | 2022-12-21 | Rx |
| 10370028011 | $2.02 | 2022-12-21 | Rx |
| 68382064006 | $2.02 | 2022-12-21 | Rx |
| 68382064016 | $2.02 | 2022-12-21 | Rx |
Generic: Dutasteride/Tamsulosin HCl | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $11.9M | 52,879 | 17,268 | $3.42 |
| 2020 | $13.2M | 59,876 | 15,024 | $3.35 |
| 2021 | $12.5M | 55,117 | 14,011 | $3.32 |
| 2022 | $11.9M | 51,757 | 13,286 | $3.34 |
| 2023 | $10.9M | 49,143 | 12,790 | $3.21 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $1.3M | 6,154 | 1,610 |
| Texas | $1.0M | 5,007 | 1,353 |
| New York | $927.7K | 4,680 | 1,235 |
| Florida | $903.4K | 3,761 | 1,118 |
| New Jersey | $868.0K | 3,268 | 912 |
| Pennsylvania | $572.1K | 2,915 | 650 |
| Michigan | $534.9K | 2,245 | 594 |
| Indiana | $338.0K | 1,402 | 355 |
| Tennessee | $293.0K | 1,251 | 324 |
| Illinois | $283.4K | 1,297 | 359 |
| Alabama | $274.0K | 1,050 | 263 |
| Georgia | $271.8K | 1,218 | 320 |
| Virginia | $258.5K | 1,169 | 318 |
| North Carolina | $252.8K | 1,156 | 303 |
| Ohio | $251.8K | 1,065 | 287 |
| Maryland | $193.3K | 879 | 249 |
| Connecticut | $176.5K | 834 | 211 |
| Louisiana | $162.5K | 858 | 198 |
| Hawaii | $148.5K | 495 | 146 |
| South Carolina | $148.2K | 697 | 188 |
| Missouri | $140.3K | 660 | 155 |
| Arizona | $138.8K | 512 | 170 |
| Kentucky | $134.6K | 653 | 157 |
| Massachusetts | $115.9K | 501 | 130 |
| Alaska | $101.9K | 305 | 90 |
| Wisconsin | $88.1K | 380 | 100 |
| Washington | $86.9K | 399 | 116 |
| Oklahoma | $82.3K | 337 | 91 |
| Delaware | $70.6K | 269 | 72 |
| Colorado | $66.2K | 260 | 70 |
| West Virginia | $63.9K | 269 | 77 |
| Arkansas | $60.5K | 278 | 72 |
| Nevada | $59.6K | 244 | 79 |
| Mississippi | $50.6K | 277 | 68 |
| Utah | $50.5K | 217 | 58 |
| Minnesota | $47.2K | 215 | 56 |
| New Mexico | $44.1K | 208 | 57 |
| Puerto Rico | $43.5K | 274 | 61 |
| Kansas | $41.7K | 175 | 46 |
| Oregon | $37.7K | 167 | 46 |
| Nebraska | $34.8K | 188 | 41 |
| Maine | $25.9K | 127 | 37 |
| Iowa | $25.1K | 125 | 32 |
| Idaho | $24.1K | 130 | 38 |
| North Dakota | $22.8K | 122 | 23 |
| Wyoming | $17.0K | 66 | 17 |
| South Dakota | $16.3K | 80 | 17 |
| Rhode Island | $15.0K | 83 | 24 |
| District of Columbia | $11.0K | 38 | 14 |
| Vermont | $10.6K | 58 | 12 |
| New Hampshire | $10.1K | 54 | 19 |
| Montana | $8.9K | 49 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.